Table 2.
Molecular markers in OCCC primary tumor samples
| Cohort | |||||
|---|---|---|---|---|---|
| Molecular marker | Method | All patients | Brazil | Costa Rica | Spain |
| HNF1B expression, n (%) | IHC | ||||
| positive | 43 (90) | 16 (80) | 7 (100) | 20 (95) | |
| negative | 5 (10) | 4 (20) | 0 (0) | 1 (5) | |
| unknown | 9 | 1 | 2 | 6 | |
| WT1 expression, n (%) | IHC | ||||
| positive | 5 (9) | 3 (14) | 1 (12) | 1 (4) | |
| negative | 51 (91) | 18 (86) | 7 (88) | 26 (96) | |
| unknown | 1 | 0 | 1 | 0 | |
| ER expression, n (%) | IHC | ||||
| positive | 4 (7) | 2 (10) | 0 (0) | 2 (7) | |
| negative | 53 (93) | 19 (90) | 9 (100) | 25 (93) | |
| PR expression, n (%) | IHC | ||||
| positive | 1 (2) | 0 (0) | 0 (0) | 1 (4) | |
| negative | 56 (98) | 21 (100) | 9 (100) | 26 (96) | |
| TP53 expression, n (%) | IHC | ||||
| aberrant | 10 (20) | 3 (17) | 3 (37) | 4 (15) | |
| normal | 42 (80) | 14 (82) | 5 (63) | 23 (85) | |
| unknown | 5 | 4 | 1 | 0 | |
| ARID1A expression, n (%) | IHC | ||||
| positive | 35 (71) | 14 (74) | 7 (87) | 14 (64) | |
| negative | 14 (29) | 5 (26) | 1 (13) | 8 (36) | |
| unknown | 8 | 2 | 1 | 5 | |
| PIK3CA mutation, n (%) | real-time PCR | ||||
| mutant | 14 (30) | 4 (25) | 3 (37) | 7 (32) | |
| wild-type | 32 (70) | 12 (75) | 5 (63) | 15 (68) | |
| unknown | 11 | 5 | 1 | 5 | |
| IHC Immunohistochemistry | |||||